aTyr Pharma, Inc. (NASDAQ:ATYR) Q4 2024 Earnings Conference Call March 13, 2025 5:00 PM ET
Company Participants
Ashlee Dunston - Senior Director of Investor Relations and Public Affairs
Sanjay Shukla - President and Chief Executive Officer
Leslie Nangle - Vice President of Research
Jill Broadfoot - Chief Financial Officer
Conference Call Participants
Derek Archila - Wells Fargo & Company
Yasmeen Rahimi - Piper Sandler Companies
Faisal Khurshid - Leerink Partners LLC
Prakhar Agrawal - Cantor Fitzgerald, L.P.
Gregory Renza - RBC Capital Markets
Joe Pantginis - H.C. Wainwright & Co.
Liang Chang - Jefferies Group LLC
Dev Prasad - Lucid Capital Markets, LLC
Operator
Good afternoon, ladies and gentlemen, and welcome to the aTyr Pharma Fourth Quarter and Full Year 2024 Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session, and instructions will be given at that time. As a reminder, this conference is being recorded for replay purposes.
It is now my pleasure to hand the conference call over to Ashlee Dunston, aTyr’s Senior Director of Investor Relations and Public Affairs. Ms. Dunston, you may begin.
Ashlee Dunston
Thank you, and good afternoon, everyone. Thank you for joining us today to discuss aTyr’s fourth quarter and full year 2024 operating results and corporate update. We are joined today by Dr. Sanjay Shukla, our President and CEO; Ms. Jill Broadfoot, our CFO; and Dr. Leslie Nangle, Vice President of Research.
On the call, Sanjay will provide an update on our corporate strategy, including our clinical program for efzofitimod. Leslie will discuss our research and discovery programs, while Jill will review the financial results and our current financial position before handing it back to Sanjay to open up the call for any questions.
Before we begin, I want to remind everyone that
- Read more current ATYR analysis and news
- View all earnings call transcripts